Surgery to remove a pancreatic tumor can sometimes result in complications. For example, after a tumor is removed and the remaining part of the pancreas is attached to the small intestine, there may be some leakage of pancreatic fluid. This fluid can form into an abscess or fistula that needs to be drained. Complications such as these occur in 15 to 20 percent of patients having surgery on the pancreas.
The purpose of this study is to see if an investigational drug called SOM230 (also called Pasireotide) can reduce the risk of these complications. Patients in this study will be randomly assigned to receive SOM230 or a placebo.